Related Experiment Video
Updated: Oct 29, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple
Angelica Giuliani1, Simona Lattanzi2, Deborah Ramini1
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
Background:
Inflamma-miRs are a group of microRNAs involved in the regulation of innate and adaptive immune responses. Increasing evidence support the contribution of dysregulated inflamma-miRs in the pathogenesis of multiple sclerosis. The aim of this study was to evaluate the expression of selected inflamma-miRs, i.e., miR-34a-5p, -125a-5p, -146a-5p, and -155, in relapsing-remitting multiple sclerosis (RRMS) and their modulation after treatment with dimethyl fumarate (DMF).
Methods:
Circulating levels of microRNAs involved in inflammatory response (inflamma-miRs) were compared between healthy controls (CTRs, n=21) and patients with RRMS (n=24) who started treatment with DMF.
Results:
Plasma levels of miR-34a (p<0.001) and miR-125a-5p (p=0.034) were higher, whereas miR-146a-5p levels were lower (p=0.041) in RRMS patients compared to CTRs. Circulating miR-125a-5p (p=0.001), miR-146a-5p (p<0.001), and miR-155 (p=0.013) were reduced after 4-month treatment with DMF. Among these, baseline and 4-month follow up miR-125a-5p (p=0.028) and miR-146a-5p (p=0.042) levels were related to disability progression.
Conclusion:
Circulating inflamma-miRs could represent candidate tools to predict MS clinical course and evaluate the effectiveness of disease-modifying treatments in RRMS.
Insights
Dysregulated inflamma-miRs (microRNAs) are linked to multiple sclerosis (MS). Dimethyl fumarate treatment modulated these inflammatory microRNAs in RRMS patients, suggesting their potential as biomarkers for disease progression and treatment efficacy.
Area of Science:
- Immunology
- Neuroscience
- Molecular Biology
Background:
- Inflamma-miRs are microRNAs crucial for immune response regulation.
- Aberrant inflamma-miR expression is implicated in multiple sclerosis (MS) pathogenesis.
- Specific inflamma-miRs evaluated include miR-34a-5p, miR-125a-5p, miR-146a-5p, and miR-155.
Purpose of the Study:
- To assess the expression levels of selected inflamma-miRs in relapsing-remitting multiple sclerosis (RRMS).
- To investigate the modulation of these inflamma-miRs following treatment with dimethyl fumarate (DMF).
Main Methods:
- Comparison of circulating inflamma-miRs between healthy controls (n=21) and RRMS patients (n=24).
- RRMS patients initiated treatment with dimethyl fumarate (DMF).
- Analysis of microRNA levels before and after 4 months of DMF treatment.
Main Results:
- RRMS patients exhibited higher plasma levels of miR-34a and miR-125a-5p, and lower levels of miR-146a-5p compared to controls.
- DMF treatment led to reduced circulating levels of miR-125a-5p, miR-146a-5p, and miR-155 after 4 months.
- Baseline and 4-month levels of miR-125a-5p and miR-146a-5p correlated with disability progression in RRMS.
Conclusions:
- Circulating inflamma-miRs show altered expression patterns in RRMS.
- DMF treatment effectively modulates specific inflamma-miRs in RRMS patients.
- These inflamma-miRs may serve as predictive biomarkers for MS clinical course and DMF treatment response.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024